Bacterial lipopolysaccharides form procollagen-endotoxin complexes that trigger cartilage inflammation and degeneration: Implications for the development of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Lorenz, Wolfgang ^a   Buhrmann, Constanze ^b   Mobasheri, Ali ^c,d,e   Lueders, Cora ^f   Shakibaei, Mehdi ^b  

^a 'Institute for Indoor Diagnostic   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF BRADFORD   (United Kingdom)

^f DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BACTERIUM LIPOPOLYSACCHARIDE; CASPASE 3; COLLAGEN FIBRIL; COLLAGEN TYPE 2; COLLAGENASE 3; CYCLOOXYGENASE 2; GELATINASE B; MULTIPROTEIN COMPLEX; PROCOLLAGEN ENDOTOXIN COMPLEX; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; WORTMANNIN; 4(2' AMINOETHYL)AMINO 1,8 DIMETHYLIMIDAZO(1,2 A)QUINOXALINE; 4(2'-AMINOETHYL)AMINO-1,8-DIMETHYLIMIDAZO(1,2-A)QUINOXALINE; ANDROSTANE DERIVATIVE; BACTERIAL TOXIN; I KAPPA B KINASE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN; PTGS2 PROTEIN, HUMAN; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; BUILDING; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE INFLAMMATION; CATABOLISM; CHONDRITIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; CARTILAGE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; IMMUNOBLOTTING; METABOLISM; OSTEOCHONDRITIS; PATHOLOGY; PHOSPHORYLATION; ULTRASTRUCTURE;

ANDROSTADIENES; APOPTOSIS; ARTHRITIS, RHEUMATOID; BACTERIAL TOXINS; CARTILAGE; CASPASE 3; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; EXTRACELLULAR MATRIX; HUMANS; I-KAPPA B KINASE; IMIDAZOLES; IMMUNOBLOTTING; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASES; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; OSTEOCHONDRITIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROCOLLAGEN; QUINOXALINES; TOLL-LIKE RECEPTOR 4;

EID: 84883609559     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4291     Document Type: Article

References (62)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
2. Feldmann M, Brennan FM, Williams RO, Elliott MJ, Maini RN. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. J Inflamm 1995, 47:90-96.
3. Lipsky PE. Why does rheumatoid arthritis involve the joints?. N Engl J Med 2007, 356:2419-2420.
4. Smolen JS, Steiner G. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum 2001, 44:2218-2220.
5. Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 2008, 22:239-252.
6. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003, 25:3-18.
7. Trenkmann M, Brock M, Ospelt C, Gay S. Epigenetics in rheumatoid arthritis. Clin Rev Allergy Immunol 2010, 39:10-19.
8. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997, 40:598-609.
9. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976, 57:1148-1157.
10. Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets 2008, 7:53-66.
11. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196.
12. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
13. Gutierrez-Ramos JC, Bluethmann H. Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunol Today 1997, 18:329-334.
14. Sehic E, Li S, Ungar AL, Blatteis CM. Complement reduction impairs the febrile response of guinea pigs to endotoxin. Am J Physiol 1998, 274:R1594-1603.
15. Ross TN, Kisiday JD, Hess T, McIlwraith CW. Evaluation of the inflammatory response in experimentally induced synovitis in the horse: a comparison of recombinant equine interleukin 1 beta and lipopolysaccharide. Osteoarthritis Cartilage 2012, 20:1583-1590.
16. Ni M, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci USA 2012, 109:267-272.
17. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995, 13:437-457.
18. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782.
19. Lorenz W, Sigrist G, Shakibaei M, Mobasheri A, Trautmann C. A hypothesis for the origin and pathogenesis of rheumatoid diseases. Rheumatol Int 2006, 26:641-654.
20. Purokivi MK, Hirvonen MR, Randell JT, Roponen MH, Meklin TM, Nevalainen AL, Husman TM, Tukiainen HO. Changes in pro-inflammatory cytokines in association with exposure to moisture-damaged building microbes. Eur Respir J 2001, 18:951-958.
21. Seuri M, Husman K, Kinnunen H, Reiman M, Kreus R, Kuronen P, Lehtomaki K, Paananen M. An outbreak of respiratory diseases among workers at a water-damaged building--a case report. Indoor Air 2000, 10:138-145.
22. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 2008, 6:1059-1070.
23. Tas SW, Remans PH, Reedquist KA, Tak PP. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 2005, 11:581-611.
24. Reddy SA, Huang JH, Liao WS. Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation. J Biol Chem 1997, 272:29167-29173.
25. Reddy SA, Huang JH, Liao WS. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J Immunol 2000, 164:1355-1363.
26. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
27. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591.
28. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008, 58:2936-2948.
29. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
30. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) 2004, 82:434-448.
31. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445.
32. Shakibaei M. Inhibition of chondrogenesis by integrin antibody in vitro. Exp Cell Res 1998, 240:95-106.
33. Busch F, Mobasheri A, Shayan P, Lueders C, Stahlmann R, Shakibaei M. Resveratrol modulates interleukin-1beta-induced phosphatidylinositol 3-kinase and nuclear factor kappaB signaling pathways in human tenocytes. J Biol Chem 2012, 287:38050-38063.
34. Shakibaei M, John T, De Souza P, Rahmanzadeh R, Merker HJ. Signal transduction by beta1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. Biochem J 1999, 342:615-623.
35. Shakibaei M, Schulze-Tanzil G, de Souza P, John T, Rahmanzadeh M, Rahmanzadeh R, Merker HJ. Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes. J Biol Chem 2001, 276:13289-13294.
36. Shakibaei M, Zimmermann B, Merker HJ. Changes in integrin expression during chondrogenesis in vitro: an immunomorphological study. J Histochem Cytochem 1995, 43:1061-1069.
37. Shakibaei M, Csaki C, Nebrich S, Mobasheri A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008, 76:1426-1439.
38. Shakibaei M, Abou-Rebyeh H, Merker HJ. Integrins in ageing cartilage tissue in vitro. Histol Histopathol 1993, 8:715-723.
39. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003, 17:1986-1995.
40. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999, 40:1-11.
41. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003, 278:1450-1456.
42. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, (109 Suppl):S81-96.
43. Metcalfe D, Harte AL, Aletrari MO, Al Daghri NM, Al Disi D, Tripathi G, McTernan PG. Does endotoxaemia contribute to osteoarthritis in obese patients?. Clin Sci (Lond) 2012, 123:627-634.
44. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004, 20:33-43.
45. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002, 14:123-128.
46. Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 2002, 72:711-717.
47. Campo GM, Avenoso A, Campo S, D'Ascola A, Nastasi G, Calatroni A. Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie 2010, 92:204-215.
48. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Rugolo CA, Calatroni A. Differential effect of molecular mass hyaluronan on lipopolysaccharide-induced damage in chondrocytes. Innate Immun 2010, 16:48-63.
49. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Sama D, Calatroni A. Purified human plasma glycosaminoglycans reduced NF-kappaB activation, pro-inflammatory cytokine production and apoptosis in LPS-treated chondrocytes. Innate Immun 2008, 14:233-246.
50. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Sama D, Calatroni A. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem 2009, 106:83-92.
51. Campo GM, Avenoso A, Campo S, Traina P, D'Ascola A, Calatroni A. Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. Arch Biochem Biophys 2009, 491:7-15.
52. Grall F, Gu X, Tan L, Cho JY, Inan MS, Pettit AR, Thamrongsak U, Choy BK, Manning C, Akbarali Y, Zerbini L, Rudders S, Goldring SR, Gravallese EM, Oettgen P, Goldring MB, Libermann TA. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003, 48:1249-1260.
53. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, Kim HY. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006, 54:2152-2163.
54. Madhavan S, Anghelina M, Sjostrom D, Dossumbekova A, Guttridge DC, Agarwal S. Biomechanical signals suppress TAK1 activation to inhibit NF-kappaB transcriptional activation in fibrochondrocytes. J Immunol 2007, 179:6246-6254.
55. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999, 9:601-604.
56. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
57. Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001, 276:27740-27744.
58. Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, Shakibaei M. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2011, 286:28556-28566.
59. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009, 11:R165.
60. Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol 2010, 130:2110-2119.
61. Creely SJ, McTernan PG, Kusminski CM, Fisher f M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-747.
62. Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000, 275:24255-24263.